I-Mab (NASDAQ: IMAB) Gets China CDE Approval To Start Phase 3 Clinical Trial Of Eftansomatropin
Hasnain R
October 1, 2020
I-Mab (NASDAQ: IMAB), a biotechnology company announced Wednesday that it has got the green signal from China Center for Drug Evaluation (CDE) to commence the